Goldman Sachs Downgrades Quest Diagnostics (DGX) to Sell
Tweet
Share
E-mail
Get Alerts DGX Hot Sheet
Price: $241.30 --0%
Rating Summary:
15 Buy, 17 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 5 | New: 25
Rating Summary:
15 Buy, 17 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 5 | New: 25
Join SI Premium – FREE
Goldman Sachs downgraded Quest Diagnostics (NYSE: DGX) from Neutral to Sell with a price target of $48 (down from $51).
The firm said they see more upside in other names in our universe. In addition volumes remain sluggish, and proposed cost savings will be back-end loaded.
For more ratings news on Quest Diagnostics click here and for the rating history of Quest Diagnostics click here.
Shares of Quest Diagnostics closed at $48.04 yesterday.
The firm said they see more upside in other names in our universe. In addition volumes remain sluggish, and proposed cost savings will be back-end loaded.
For more ratings news on Quest Diagnostics click here and for the rating history of Quest Diagnostics click here.
Shares of Quest Diagnostics closed at $48.04 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Downgrades Limbach Holdings (LMB) to Underweight
- Goldman Sachs Downgrades Kuaishou Technology (1024:HK) to Neutral
- Nomura/Instinet Downgrades Pop Mart International Group Ltd (9992:HK) to Neutral
Create E-mail Alert Related Categories
Downgrades, Hot DowngradesRelated Entities
Goldman SachsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
